Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Eli Lilly and Co stock

LLY
US5324571083
858560

Price

878.31
Today +/-
+7.69
Today %
+0.91 %

Eli Lilly and Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Eli Lilly and Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Eli Lilly and Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Eli Lilly and Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Eli Lilly and Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Eli Lilly and Co Stock Price History

DateEli Lilly and Co Price
2/6/2025878.31 undefined
2/5/2025870.37 undefined
2/4/2025842.18 undefined
2/3/2025826.07 undefined
2/2/2025810.43 undefined
1/30/2025811.08 undefined
1/29/2025823.23 undefined
1/28/2025804.08 undefined
1/27/2025804.99 undefined
1/26/2025808.17 undefined
1/23/2025785.41 undefined
1/22/2025766.60 undefined
1/21/2025753.98 undefined
1/20/2025742.35 undefined
1/16/2025725.72 undefined
1/15/2025757.60 undefined
1/14/2025746.74 undefined
1/13/2025744.91 undefined
1/12/2025797.48 undefined
1/9/2025799.90 undefined

Eli Lilly and Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Eli Lilly and Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eli Lilly and Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eli Lilly and Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Eli Lilly and Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Eli Lilly and Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Eli Lilly and Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eli Lilly and Co’s growth potential.

Eli Lilly and Co Revenue, EBIT and net profit per share

DateEli Lilly and Co RevenueEli Lilly and Co EBITEli Lilly and Co Net Income
2030e110.28 B undefined0 undefined50.81 B undefined
2029e100.48 B undefined49.21 B undefined45.07 B undefined
2028e90.98 B undefined43.72 B undefined39.69 B undefined
2027e79.6 B undefined35.65 B undefined32.78 B undefined
2026e70.31 B undefined31.53 B undefined28.24 B undefined
2025e59.8 B undefined24.46 B undefined21.63 B undefined
2024e45.56 B undefined14.66 B undefined12.55 B undefined
202334.12 B undefined10.33 B undefined5.24 B undefined
202228.54 B undefined8.28 B undefined6.25 B undefined
202128.32 B undefined7.55 B undefined5.58 B undefined
202024.54 B undefined6.85 B undefined6.19 B undefined
201922.32 B undefined5.79 B undefined8.32 B undefined
201821.49 B undefined5.79 B undefined3.23 B undefined
201719.97 B undefined4.45 B undefined-204 M undefined
201621.22 B undefined3.87 B undefined2.74 B undefined
201519.96 B undefined3.59 B undefined2.41 B undefined
201419.62 B undefined3.33 B undefined2.39 B undefined
201323.11 B undefined5.55 B undefined4.69 B undefined
201222.6 B undefined5.02 B undefined4.09 B undefined
201124.29 B undefined6.32 B undefined4.35 B undefined
201023.08 B undefined6.77 B undefined5.07 B undefined
200921.84 B undefined6.37 B undefined4.33 B undefined
200820.37 B undefined5.53 B undefined-2.07 B undefined
200718.63 B undefined4.8 B undefined2.95 B undefined
200615.69 B undefined4.13 B undefined2.66 B undefined
200514.65 B undefined3.65 B undefined1.98 B undefined
200413.86 B undefined3.66 B undefined1.81 B undefined

Eli Lilly and Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
3.033.112.923.323.243.614.185.195.734.965.25.716.7677.999.241010.8611.5411.0812.5813.8614.6515.6918.6320.3721.8423.0824.2922.623.1119.6219.9621.2219.9721.4922.3224.5428.3228.5434.1245.5659.870.3179.690.98100.48110.28
-2.47-6.1113.84-2.6211.4615.7724.3310.29-13.334.769.8718.423.4614.1515.648.298.596.27-4.0313.5910.135.687.1418.769.337.195.685.25-6.932.26-15.131.756.33-5.887.603.859.9515.400.7919.5633.5231.2517.5813.2214.2910.459.75
63.6563.7263.0763.1466.4468.8169.9269.4370.0071.4572.1570.5972.1273.2575.6478.1979.0381.0881.2880.3578.7376.7476.2877.4077.2078.5180.5581.0879.1378.7878.7774.8574.7673.3577.7378.2278.8477.6674.1876.7779.2459.3545.2238.4633.9729.7226.9124.52
1.931.981.842.12.152.482.923.614.013.553.754.034.885.136.047.227.918.819.388.99.9110.6311.1712.1514.391617.5918.7119.2217.8118.2114.6814.9215.5715.5316.8117.619.0621.0121.9127.040000000
0.460.490.520.560.640.760.941.131.320.710.481.292.291.52-0.392.12.723.062.782.712.561.811.982.662.95-2.074.335.074.354.094.692.392.412.74-0.23.238.326.195.586.255.2412.5521.6328.2432.7839.6945.0750.81
-7.225.717.7215.4118.1723.5219.8916.68-46.08-32.30167.9278.15-33.65-125.53-640.2129.8212.39-9.09-2.59-5.43-29.329.3934.4910.89-170.17-308.9317.12-14.24-5.9614.58-48.960.7113.70-107.45-1,684.31157.36-25.53-9.8811.88-16.09139.5072.3730.5316.1021.0713.5512.75
------------------------------------------------
------------------------------------------------
1.21.181.141.161.181.151.171.161.171.181.181.171.151.121.131.121.111.11.091.091.081.091.091.091.091.091.11.111.111.121.091.071.071.061.051.030.940.910.910.910.90000000
------------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Eli Lilly and Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Eli Lilly and Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                                 
0.490.450.410.491.030.760.650.750.780.730.990.751.080.962.031.63.844.623.733.663.717.465.043.894.835.934.56.736.95.685.44.834.456.048.037.412.443.683.912.212.93
0.540.560.610.690.650.690.730.770.840.90.951.551.521.481.541.971.441.631.411.671.872.062.312.32.672.783.343.493.63.343.433.243.514.034.555.784.555.886.676.99.09
0.060.070.080.090.280.070.110.110.2900.190.290.290.260.340.280.40.340.290.40.480.490.450.41.030.50.490.660.640.550.590.570.560.740.72011.051.451.662.25
0.630.630.690.70.620.670.60.670.80.941.10.970.840.880.910.90.881.061.51.962.291.882.272.522.492.852.522.32.642.932.743.453.564.463.13.193.983.894.315.77
0.110.120.150.110.150.10.180.20.230.440.470.410.410.320.510.570.480.480.450.580.750.531.120.91.260.761.311.440.810.820.760.560.60.741.454.272.542.872.532.955.69
1.831.831.942.072.732.292.282.52.943.013.73.964.143.895.325.417.067.946.947.88.7712.8410.89.7512.3212.4512.4914.8414.2513.0413.1111.9312.5715.119.220.5513.7117.4618.4518.0425.73
1.211.281.371.531.641.812.122.943.784.074.24.414.244.314.14.13.984.184.535.296.547.557.918.158.588.638.27.947.767.767.987.968.058.258.8388.418.688.9910.1412.91
0.130.190.260.270.290.410.530.480.280.240.220.460.570.440.470.20.180.42.713.153.380.561.310.581.551.161.784.036.317.634.573.655.215.682.011.962.973.212.93.05
00000000000000000000000000000000000000000
0.010.090.090.480.40.410.450.470.430.460.414.4100000000.10.110.140.130.131.712.762.533.43.223.192.812.885.044.364.031.076.627.457.697.216.91
0000000000004.114.031.551.520.120.120.09000000.751.171.181.421.911.571.521.764.043.974.371.373.683.773.894.074.94
0.230.260.280.240.210.350.480.760.880.891.11.261.361.641.141.371.492.062.162.72.93.784.453.012.952.661.921.622.492.532.217.22.221.912.8710.924.916.316.577.1310.47
1.581.822.012.522.532.973.584.645.365.675.9310.5510.2710.427.267.195.776.759.511.2412.9212.0313.7912.2914.5616.7614.9716.1619.4121.3622.1524.382323.7125.7823.3625.5829.1730.3531.4638.28
3.413.643.954.65.265.265.857.148.38.679.6214.5114.4114.3112.5812.612.8314.6916.4319.0421.6924.8724.5822.0426.8829.2127.463133.6634.435.2536.3135.5738.8144.9843.9139.2946.6348.8149.4964.01
                                                                                 
484891919191177178183183183183356356695687682704703702702708707708710711719721724717699695691689688661599598596594593.6
0.140.130.120.180.050.03000.340.310.30.420.420.070002.612.612.612.613.123.323.573.813.984.644.84.894.965.055.295.555.645.826.586.696.786.836.927.25
2.232.52.743.043.43.834.074.554.694.744.55.066.487.214.54.234.996.227.418.59.479.7310.0310.7711.817.669.8312.7314.916.0916.9916.4816.0116.0513.8911.44.927.838.9610.0410.31
-114-156-118-893-19-177-81-235-334-407-256-201-234-437-377-546-746-877-794-279107-527-1,490-82-2,873-2,549-2,851-3,873-3,870-2,208-4,092-4,591-5,498-5,832-5,729-6,529-6,511-4,347-3,808-4,300.8
00000000000000000000000000012915732051001022411405154-37-26.2
2.32.522.843.233.543.924.074.654.984.94.575.417.067.44.764.545.128.799.8511.0212.513.6613.5313.5616.249.4712.6415.5316.6517.9720.7418.4817.6717.114.6812.915.688.7112.0513.7113.83
0.110.120.120.150.170.180.20.260.280.320.330.881.020.830.991.190.450.660.620.680.880.650.780.790.920.890.971.071.131.191.121.131.341.351.411.211.411.611.671.932.6
0.130.140.170.20.20.250.290.370.30.270.330.310.320.390.460.70.490.470.380.230.390.951.041.151.531.6422.222.582.722.892.833.534.815.465.815.856.857.89.8413.34
0.440.470.450.540.840.690.710.951.011.211.751.761.721.792.522.542.763.653.913.614.13.983.163.12.574.733.573.473.714.473.93.13.362.893.963.773.024.024.043.864.45
0.310.340.30.230.240.130.131.240.690.590.532.721.731.090.030.030.030.020.270.260.021.650.010.220.415.850.030.161.520.010001.32.70.51.49001.56.19
0000000000000.180.130.20.150.220.160.010.290.180.370.7200000001.012.690.010.641.010.60.010.011.5400.72
0.991.071.051.121.451.241.332.822.272.42.935.674.974.224.194.613.944.965.25.065.567.65.725.255.4413.116.576.938.938.398.929.748.2310.9914.5411.8911.7812.4815.0517.1427.29
0.090.120.240.40.370.390.270.280.40.580.842.132.592.522.332.192.812.633.134.364.694.495.763.494.594.626.646.775.475.524.25.337.978.379.949.213.8216.5915.3514.7418.32
0.210.240.280.30.30.410.490.350.420.170.130.190.30.380.220.250.140.09000.390.620.70.060.290.080000000001.312.192.11.730.090
0000.050.1000.230.250.631.161.171.131.091.041.130.930.9611.351.291.241.612.413.054.684.734.895.735.724.495.854.785.378.8410.68.819.647.526.757.53
0.310.360.520.740.770.80.760.861.061.382.133.484.013.993.583.563.883.684.135.716.366.358.075.977.949.3711.3711.6611.1911.248.6911.1812.7513.7418.7821.1124.8128.3324.621.5825.85
1.291.421.571.862.212.042.093.683.333.785.069.158.988.217.778.177.818.649.3310.7711.9213.9513.7911.2213.3722.4817.9418.5920.1219.6317.6120.9220.9824.7333.323336.5940.8139.6538.7253.14
3.593.944.45.085.755.966.168.328.318.689.6314.5616.0415.612.5312.7112.9417.4419.1821.7924.4327.6127.3224.7829.6131.9530.5734.1236.7837.638.3539.438.6541.834845.9142.2749.5251.752.4366.97
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Eli Lilly and Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Eli Lilly and Co's financial health and stability.

Assets

Eli Lilly and Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Eli Lilly and Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Eli Lilly and Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Eli Lilly and Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.540.410.760.941.131.310.710.481.292.291.52-0.392.12.723.062.782.712.561.811.982.662.95-2.074.335.074.354.094.682.392.412.74-0.23.238.326.195.586.245.24
0.170.180.20.230.250.30.370.40.430.550.540.510.490.440.440.450.490.550.60.730.81.051.121.31.331.371.461.451.381.431.51.571.611.231.321.551.521.53
0000-5-13-184-231172144207-2932527-442273346130772-347346122442189559-26812628536-748439-78732662-134-802-2,185-2,341
0.10.32-0.11-0.160.16-0.34-0.08-0.13-0.42-0.23-0.190.480.11-0.430.78-0.08-1.540.08-1.24-1.95-0.8-0.122.35-0.96-0.191.25-0.05-0.39-0.33-1.14-0.483.2-2.38-1.69-0.75-1.02-0.01-3.06
0.06-0.12-0.170.02-0.05-0.010.6710.06-0.93-0.12.090.15-0.02-0.10.230.070.320.931.50.961.155.71-0.160.320.68-0.18-0.141.131.230.922.123.01-2.780.172.31.893.5
004641445372631022712922431881701951715444038305159203205176167171139140129146192223305345338323404
000.530.360.410.490.480.460.380.450.290.540.270.250.290.320.860.610.491.780.861.01-0.051.140.860.940.991.260.730.970.70.251.11.180.951.62.675.56
0.870.80.691.031.471.251.481.521.531.821.992.42.882.743.733.662.073.652.871.913.985.157.34.346.867.235.35.744.462.964.855.625.524.846.57.267.084.24
-321-215-420-549-1,075-1,243-972-703-649-605-443-366-419-528-677-1,043-1,214-1,706-1,928-1,298-1,077-1,193-1,069-855-1,186-1,692-1,044-1,093-1,565-1,626-1,092-2,163-3,018-1,353-2,029-1,873-2,484-7,392
-0.420.11-0.26-0.82-1.06-0.86-0.93-0.87-4.41-0.56-0.470.81-0.371.09-1.06-3.96-2.47-1.33-0.68-2.220.61-4.33-7.270.14-3.16-4.82-2.83-2.07-3.910.03-3.14-3.781.91-8.08-2.26-2.76-3.26-7.15
-0.10.320.16-0.280.020.390.04-0.16-3.760.04-0.021.180.051.62-0.38-2.92-1.260.381.24-0.921.69-3.13-6.21-1.97-3.13-1.79-0.98-2.341.65-2.05-1.624.92-6.73-0.23-0.89-0.780.24
00000000000000000000000000000000000000
-0.080-0.07-0.011.1-0.620.10.193.430.03-0.81-1.15-0.180.69-0.230.591.230.041.640.01-2.790.984.41-3.420.12-0.2-1.51-0.012.64-0.182.53-0.734.690.290.5-0.068.65
-107-213-282-158-1,045925-42-6132-101-9614-1,930-1,265-874-436-320-178104-272-62240000-721-1,698-800-749-600-299-2,491-4,400-500-1,250-1,500-750
-0.42-0.46-0.67-0.54-0.39-0.28-0.59-0.522.84-0.81-1.66-1.95-2.98-1.58-2.23-1.05-0.42-1.580.2-1.88-4.58-0.842.35-5.53-2.02-2.37-4.42-3.83-0.17-3.11-0.560.14-5.9-2.32-3.14-4.13-5.413.5
1937000000000000000003990-8421960096-52-300-364-372-200-241-295-308-335
-250-278-316-372-450-582-643-708-723-747-753-818-877-1,000-1,126-1,207-1,335-1,443-1,539-1,654-1,736-1,853-2,056-2,152-2,165-2,180-2,187-2,120-2,101-2,127-2,158-2,192-2,311-2,409-2,687-3,086-3,535-4,069
0.050.49-0.25-0.340.030.13-0.050.11-00.46-0.191.13-0.452.20.41-1.41-0.760.812.61-2.360.10.112.28-1.031.53-0.07-1.9-0.190.04-0.210.921.951.46-5.661.320.16-1.750.75
548.2579.7269.5483.6399.311.3511813.3882.91,219.21,547.52,034.12,456.42,214.13,053.62,618855.81,940.1941.5615.52,898.13,961.16,226.43,480.55,670.15,541.64,260.64,641.72,892.51,338.43,7593,4522,506.33,483.14,470.55,387.54,600.4-3,152
00000000000000000000000000000000000000

Eli Lilly and Co stock margins

The Eli Lilly and Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eli Lilly and Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eli Lilly and Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Eli Lilly and Co's sales revenue. A higher gross margin percentage indicates that the Eli Lilly and Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Eli Lilly and Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Eli Lilly and Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eli Lilly and Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eli Lilly and Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eli Lilly and Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Eli Lilly and Co Margin History

Eli Lilly and Co Gross marginEli Lilly and Co Profit marginEli Lilly and Co EBIT marginEli Lilly and Co Profit margin
2030e79.25 %0 %46.07 %
2029e79.25 %48.97 %44.85 %
2028e79.25 %48.05 %43.62 %
2027e79.25 %44.79 %41.18 %
2026e79.25 %44.84 %40.16 %
2025e79.25 %40.91 %36.18 %
2024e79.25 %32.17 %27.55 %
202379.25 %30.26 %15.36 %
202276.77 %29.01 %21.88 %
202174.18 %26.65 %19.71 %
202077.66 %27.91 %25.24 %
201978.84 %25.94 %37.27 %
201878.22 %26.92 %15.04 %
201777.73 %22.26 %-1.02 %
201673.35 %18.25 %12.9 %
201574.76 %18 %12.06 %
201474.85 %16.97 %12.19 %
201378.77 %24 %20.27 %
201278.78 %22.19 %18.09 %
201179.13 %26.01 %17.9 %
201081.08 %29.35 %21.97 %
200980.55 %29.17 %19.83 %
200878.51 %27.13 %-10.17 %
200777.2 %25.78 %15.85 %
200677.4 %26.3 %16.97 %
200576.28 %24.91 %13.52 %
200476.74 %26.4 %13.06 %

Eli Lilly and Co Stock Sales Revenue, EBIT, Earnings per Share

The Eli Lilly and Co earnings per share therefore indicates how much revenue Eli Lilly and Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Eli Lilly and Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Eli Lilly and Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Eli Lilly and Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Eli Lilly and Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eli Lilly and Co Revenue, EBIT and net profit per share

DateEli Lilly and Co Sales per ShareEli Lilly and Co EBIT per shareEli Lilly and Co Earnings per Share
2030e116.17 undefined0 undefined53.52 undefined
2029e105.85 undefined0 undefined47.47 undefined
2028e95.84 undefined0 undefined41.81 undefined
2027e83.85 undefined0 undefined34.53 undefined
2026e74.06 undefined0 undefined29.74 undefined
2025e62.99 undefined0 undefined22.79 undefined
2024e47.99 undefined0 undefined13.22 undefined
202337.78 undefined11.43 undefined5.8 undefined
202231.54 undefined9.15 undefined6.9 undefined
202131.05 undefined8.28 undefined6.12 undefined
202026.88 undefined7.5 undefined6.78 undefined
201923.85 undefined6.19 undefined8.89 undefined
201820.79 undefined5.6 undefined3.13 undefined
201718.99 undefined4.23 undefined-0.19 undefined
201619.98 undefined3.65 undefined2.58 undefined
201518.72 undefined3.37 undefined2.26 undefined
201418.26 undefined3.1 undefined2.23 undefined
201321.3 undefined5.11 undefined4.32 undefined
201220.24 undefined4.49 undefined3.66 undefined
201121.8 undefined5.67 undefined3.9 undefined
201020.86 undefined6.12 undefined4.58 undefined
200919.89 undefined5.8 undefined3.94 undefined
200818.62 undefined5.05 undefined-1.89 undefined
200717.08 undefined4.4 undefined2.71 undefined
200614.44 undefined3.8 undefined2.45 undefined
200513.41 undefined3.34 undefined1.81 undefined
200412.73 undefined3.36 undefined1.66 undefined

Eli Lilly and Co business model

Eli Lilly and Co. is a global biopharmaceutical company headquartered in Indianapolis, Indiana, USA. The company was founded in 1876 by Colonel Eli Lilly with the aim of manufacturing pharmaceutical products of the highest quality. Eli Lilly began his career in the pharmacy industry and opened his own pharmacy in Indianapolis in 1876. He quickly developed his own medications and eventually established Eli Lilly and Company in 1901. Over the years, the company has continued to evolve and expand its business into numerous areas. Eli Lilly is focused on biopharmaceutical research and development and operates in areas such as oncology, diabetes, neurology, and others. The company's main goal is to develop drugs that can change and improve lives. Eli Lilly invests a high percentage of its revenue into research and development every year. The company has several strategic business units, including human pharmaceuticals, animal pharmaceuticals, and oncology research. Eli Lilly is divided into five main divisions: diabetes, oncology, immunology, neurology, and animal health. The diabetes division focuses on manufacturing insulin products and glucose sensors for the treatment of type 1 and type 2 diabetes, as well as blood glucose meters and other diabetes products. The oncology division focuses on researching and developing drugs to treat cancer. The company currently has several compounds in clinical trials, including a new preparation for the treatment of breast cancer. The immunology division focuses on products for the treatment of autoimmune and inflammatory diseases, such as psoriasis. The neurology division focuses on researching and developing drugs to treat diseases of the nervous system, such as Alzheimer's. The animal health division focuses on animal health products, such as drugs for the treatment of infections in livestock and pets. Eli Lilly is primarily known for its insulin products and treatments in the field of oncology. Some of the company's most well-known products include Humalog, Forteo, Alimta, and Cymbalta. The effectiveness and compliance of the products are monitored by a quality and safety system to ensure that patients receive the highest quality medications. In conclusion, Eli Lilly and Co. is a company with a long history and a unique business model. The company specializes in developing high-quality pharmaceutical products and has continued to evolve since its founding. Eli Lilly has become a leader in various areas such as diabetes, oncology, immunology, neurology, and animal health. They are known for their insulin products and treatments in the field of oncology. The company remains committed to expanding its reach and presence globally and continues to develop innovative products that can improve and change people's lives. Eli Lilly and Co is one of the most popular companies on Eulerpool.com.

Eli Lilly and Co SWOT Analysis

Strengths

Eli Lilly and Co has a strong global presence in the pharmaceutical industry, with a wide range of innovative and diverse product portfolio.

The company has a strong research and development (R&D) capability, investing heavily in cutting-edge technology and scientific advancements.

Eli Lilly has a strong brand reputation and is recognized for its commitment to quality and patient safety.

Weaknesses

Eli Lilly faces significant competition from other pharmaceutical companies, which could impact its market share and profitability.

The company is heavily reliant on a few key products for its revenue, leaving it vulnerable to patent expirations and generic substitutions.

Eli Lilly has faced regulatory challenges in the past, which could impact its ability to gain approval for new products and expand into new markets.

Opportunities

The increasing demand for personalized medicine and advancements in biotechnology present opportunities for Eli Lilly to develop targeted therapies for various diseases.

Expansion into emerging markets, such as China and India, provides a significant growth opportunity for the company.

Partnerships and collaborations with academic institutions and other pharmaceutical companies can enhance Eli Lilly's R&D capabilities and accelerate innovation.

Threats

The pharmaceutical industry is highly regulated, and changes in government regulations could impact Eli Lilly's operations and profitability.

The emergence of new competitors and the potential entry of tech giants into the healthcare industry pose threats to Eli Lilly's market position.

There is always a risk of unexpected adverse events or negative clinical trial results, which could impact the company's reputation and financial performance.

Eli Lilly and Co Revenue by Segment

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eli Lilly and Co Revenue by Segment

Segmente20172016201520142013
Collaboration and other revenue-----
Net product revenue-----
Collaboration and other revenue associated with prior period transfers of intellectual property-----
Basaglar-----
Effient-----
Erbitux-----
Jardiance-----
Trajenta-----

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eli Lilly and Co Revenue by Segment

Segmente20172016201520142013
Cymbalta----3.96 B USD
Erbitux645.9 M USD687 M USD485 M USD-373.7 M USD
Effient388.9 M USD535.2 M USD523 M USD--
Basaglar432.1 M USD----
Trajenta (BI)--356.8 M USD--
Exenatide----133.1 M USD
Diabetes-----
Immunology-----
Neuroscience-----
Oncology-----
Other-----
Diabetes and Obesity-----
Olumiant®-----

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eli Lilly and Co Revenue by Segment

Segmente20172016201520142013
Cymbalta757.2 M USD930.5 M USD1.03 B USD--
Basaglar®-----
Jardiance®-----
Trajenta®-----
COVID-19 antibodies-----
Olumiant®-----
Tyvyt®-----
Cardiovascular:-----
Endocrinology-----
Immunology:-----
Neuroscience:-----
Oncology:-----
Other human pharmaceutical products-----

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eli Lilly and Co Revenue by Segment

Segmente20172016201520142013
Endocrinology10.09 B USD----
Oncology:3.81 B USD----
Cardiovascular:2.87 B USD----
Neuroscience:2.17 B USD----
Immunology:605.1 M USD----
Other human pharmaceutical products241.3 M USD----
Olumiant®-----
COVID-19 antibodies-----
Immunology-----
Neuroscience-----
Oncology-----
Other-----
Collaboration and other revenue-----
Net product revenue-----
Royalty-----

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eli Lilly and Co Revenue by Segment

Segmente20172016201520142013
Endocrinology-8.08 B USD---
Humalog-2.77 B USD2.84 B USD--
Cialis-2.47 B USD2.31 B USD--
Alimta-2.28 B USD2.49 B USD--
Oncology-3.72 B USD---
Cardiovascular-3.23 B USD---
Forteo-1.5 B USD1.35 B USD--
Neuroscience-2.72 B USD---
Humulin-1.37 B USD1.31 B USD--
Zyprexa-725.3 M USD940.3 M USD--
Strattera-854.7 M USD784 M USD--
Other Endocrinology-913.6 M USD696.4 M USD--
Trulicity [Member]-925.5 M USD248.7 M USD--
Cyramza-614.1 M USD383.8 M USD--
Other Cardiovascular-218.6 M USD234.3 M USD--
Evista-172.4 M USD237.3 M USD--
Other Neuroscience-209.8 M USD183.5 M USD--
Other Pharmaceuticals-313.6 M USD---
Other Oncology-137.4 M USD147.9 M USD--
COVID-19 Antibodies-----
Tyvyt®-----
Bamlanivimab-----
Tyvyt-----
Collaboration and other revenue-----
Net product revenue-----
Collaboration and other revenue associated with prior period transfers of intellectual property-----

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eli Lilly and Co Revenue by Segment

Segmente20172016201520142013
Alimta---2.79 B USD-
Humalog---2.79 B USD-
Cialis---2.29 B USD-
Cymbalta---1.61 B USD-
Humulin---1.4 B USD-
Forteo---1.32 B USD-
Zyprexa---1.04 B USD-
Strattera---738.5 M USD-
Other Endocrinology---683.1 M USD-
Evista---419.8 M USD-
Other Cardiovascular---240.3 M USD-
Other Oncology---227.7 M USD-
Other Neuroscience---206 M USD-
Cialis®-----

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eli Lilly and Co Revenue by Segment

Segmente20172016201520142013
Effient---522.2 M USD-
Erbitux---373.3 M USD-
Trajenta (BI)---328.8 M USD-
Basaglar-----
Jardiance-----
Olumiant-----
Tyvyt®-----
Trajenta-----
Basaglar®-----
Jardiance®-----
Trajenta®-----
Alimta-----

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eli Lilly and Co Revenue by Segment

Segmente20172016201520142013
Human Pharmaceutical Products Total--16.78 B USD17.27 B USD-
Endocrinology--7.04 B USD6.94 B USD7.3 B USD
Pharmaceutical Products Total----20.96 B USD
Human pharmaceutical products19.79 B USD----
Human Pharmaceutical Products-18.06 B USD---
Neuroscience--2.94 B USD3.6 B USD7.22 B USD
Oncology--3.51 B USD3.39 B USD3.27 B USD
Cardiovascular--3.07 B USD3.05 B USD2.92 B USD
Animal Health Products-3.16 B USD-2.35 B USD2.15 B USD
Animal health products3.09 B USD----
Other Pharmaceuticals--227.7 M USD287 M USD249.3 M USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Eli Lilly and Co Revenue by Segment

Segmente20172016201520142013
Animal Health Products--3.18 B USD--

Eli Lilly and Co Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Eli Lilly and Co Revenue by Segment

DateChinaEuropeJapanJAPANOther foreign countriesOther Foreign CountriesOutside U.SU.SUnited States
20231.54 B USD6.17 B USD1.67 B USD-2.95 B USD-12.33 B USD21.79 B USD-
20221.45 B USD4.3 B USD1.75 B USD-2.85 B USD-10.35 B USD18.19 B USD-
20211.66 B USD4.78 B USD2.37 B USD-2.7 B USD-11.51 B USD16.81 B USD-
20201.12 B USD4.19 B USD2.58 B USD-2.42 B USD-10.31 B USD14.23 B USD-
2019-3.77 B USD2.55 B USD-3.28 B USD---12.72 B USD
2018-4.23 B USD-2.49 B USD3.96 B USD-9.06 B USD-12.35 B USD
2017-3.94 B USD-2.42 B USD3.72 B USD---12.79 B USD
2016-3.77 B USD-2.33 B USD-3.62 B USD--11.51 B USD
2015-3.94 B USD-2.03 B USD-3.88 B USD--10.1 B USD
2014-4.51 B USD-2.03 B USD-3.95 B USD--9.13 B USD
2013-4.34 B USD2.06 B USD--3.82 B USD--3.96 B USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Eli Lilly and Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Eli Lilly and Co historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Eli Lilly and Co shares outstanding

The number of shares was Eli Lilly and Co in 2024 — This indicates how many shares 903.284 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Eli Lilly and Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Eli Lilly and Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Eli Lilly and Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Eli Lilly and Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eli Lilly and Co stock splits

In Eli Lilly and Co's history, there have been no stock splits.

Eli Lilly and Co dividend history and estimates

In 2024, Eli Lilly and Co paid a dividend amounting to 5.2 USD. Dividend means that Eli Lilly and Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Eli Lilly and Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Eli Lilly and Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Eli Lilly and Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Eli Lilly and Co Dividend History

DateEli Lilly and Co Dividend
2030e5.73 undefined
2029e5.74 undefined
2028e5.73 undefined
2027e5.73 undefined
2026e5.75 undefined
2025e5.73 undefined
2024e5.72 undefined
20234.52 undefined
20223.92 undefined
20213.4 undefined
20202.96 undefined
20192.58 undefined
20182.25 undefined
20172.08 undefined
20163.06 undefined
20152.5 undefined
20141.96 undefined
20131.96 undefined
20121.96 undefined
20111.96 undefined
20101.96 undefined
20091.96 undefined
20081.88 undefined
20071.7 undefined
20061.6 undefined
20051.52 undefined
20041.42 undefined

Eli Lilly and Co dividend payout ratio

In 2024, Eli Lilly and Co had a payout ratio of 54.78%. The payout ratio indicates the percentage of the company's profits that Eli Lilly and Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Eli Lilly and Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Eli Lilly and Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Eli Lilly and Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Eli Lilly and Co Payout Ratio History

DateEli Lilly and Co Payout ratio
2030e54.23 %
2029e54.11 %
2028e54.22 %
2027e54.36 %
2026e53.77 %
2025e54.53 %
2024e54.78 %
202351.99 %
202256.81 %
202155.56 %
202043.59 %
201929.05 %
201872.12 %
2017-1,094.74 %
2016118.6 %
2015110.62 %
201487.89 %
201345.37 %
201253.55 %
201150.26 %
201042.79 %
200949.75 %
2008-99.47 %
200762.73 %
200665.31 %
200583.06 %
200485.54 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Eli Lilly and Co.

Eli Lilly and Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20241.48 1.18  (-20.34 %)2024 Q3
6/30/20242.62 3.92  (49.43 %)2024 Q2
3/31/20242.48 2.58  (3.91 %)2024 Q1
12/31/20232.24 2.49  (11.11 %)2023 Q4
9/30/2023-0.14 0.1  (173.58 %)2023 Q3
6/30/20232 2.11  (5.55 %)2023 Q2
3/31/20231.75 1.62  (-7.16 %)2023 Q1
12/31/20221.8 2.09  (16.25 %)2022 Q4
9/30/20221.94 1.98  (2.27 %)2022 Q3
6/30/20221.71 1.25  (-26.71 %)2022 Q2
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Eli Lilly and Co stock

Eulerpool World ESG Rating (EESG©)

64/ 100

🌱 Environment

79

👫 Social

84

🏛️ Governance

29

Environment

Scope 1 - Direct Emissions
171,000
Scope 2 - Indirect emissions from purchased energy
415,000
Scope 3 - Indirect emissions within the value chain
3,179,000
Total CO₂ emissions
586,000
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees51
Percentage of women in management
Percentage of Asian employees11
Share of Asian management
Percentage of Hispanic/Latino employees6
Hispano/Latino Management share
Percentage of Black employees10
Black Management Share
Percentage of white employees70
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Eli Lilly and Co shareholders

%
Name
Stocks
Change
Date
10.20646 % Lilly Endowment, Inc.96,891,978-24,0849/30/2024
7.74347 % The Vanguard Group, Inc.73,510,2781,109,8906/30/2024
5.39001 % PNC Investments LLC51,168,424-25,3536/30/2024
4.43978 % BlackRock Institutional Trust Company, N.A.42,147,720810,9196/30/2024
3.56861 % State Street Global Advisors (US)33,877,562-381,0046/30/2024
3.40033 % Fidelity Management & Research Company LLC32,280,020-586,4576/30/2024
2.29783 % Capital World Investors21,813,763-2,722,2926/30/2024
2.06654 % PRIMECAP Management Company19,618,082-1,636,1086/30/2024
2.05615 % T. Rowe Price Associates, Inc.19,519,4866,9996/30/2024
1.79130 % Geode Capital Management, L.L.C.17,005,148429,9526/30/2024
1
2
3
4
5
...
10

Eli Lilly and Co Executives and Management Board

Mr. David Ricks

(55)
Eli Lilly and Co Chairman of the Board, President, Chief Executive Officer (since 2012)
Compensation 21.4 M

Dr. Daniel Skovronsky

(49)
Eli Lilly and Co Chief Scientific Officer, President of Lilly Research Laboratories, President of Lilly Immunology
Compensation 8.46 M

Mr. Jacob Van Naarden

(38)
Eli Lilly and Co Executive Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly Oncology
Compensation 6.12 M

Ms. Anat Hakim

(53)
Eli Lilly and Co Executive Vice President, General Counsel, Secretary
Compensation 5.43 M

Ms. Anat Ashkenazi

(50)
Eli Lilly and Co Chief Financial Officer, Executive Vice President
Compensation 5.26 M
1
2
3
4
5
...
6

Eli Lilly and Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Box A Stock
Box A
SupplierCustomer0,940,930,370,710,810,83
Alexandria Real Estate Stock
Alexandria Real Estate
SupplierCustomer0,940,860,850,940,860,81
Chinook Therapeutics Stock
Chinook Therapeutics
SupplierCustomer0,930,87-0,60-0,69-0,310,43
Pfizer Stock
Pfizer
SupplierCustomer0,920,880,880,860,720,71
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,910,95 0,810,350,27
Sanofi Stock
Sanofi
SupplierCustomer0,910,970,390,330,41-0,04
Chugai Pharmaceutical Stock
Chugai Pharmaceutical
SupplierCustomer0,900,70-0,20-0,23-0,280,31
Affimed N.V. Stock
Affimed N.V.
SupplierCustomer0,890,40-0,54-0,860,330,71
Sanofi Stock
Sanofi
SupplierCustomer0,870,620,100,74
Bayer Stock
Bayer
SupplierCustomer0,870,95-0,49-0,820,20-0,52
1
2
3
4
5
...
6

Most common questions regarding Eli Lilly and Co

What values and corporate philosophy does Eli Lilly and Co represent?

Eli Lilly and Co is a renowned pharmaceutical company with a strong set of values and corporate philosophy. They prioritize patient well-being and improving lives through their innovative healthcare solutions. Their commitment to integrity and high ethical standards reflects in their extensive research and development efforts. Eli Lilly and Co aims to provide quality products that address unmet medical needs while fostering a culture of inclusivity and diversity within their organization. By consistently adhering to their core values, the company has become a global leader and a trustworthy partner in the pharmaceutical industry.

In which countries and regions is Eli Lilly and Co primarily present?

Eli Lilly and Co is primarily present in various countries and regions worldwide. The company's global presence extends to markets such as the United States, Europe, Asia, and Latin America. With a strong foothold in the pharmaceutical industry, Eli Lilly and Co operates across multiple continents, including North America, where it is headquartered in Indianapolis, Indiana. Additionally, the company's international operations expand into key pharmaceutical markets like Canada, Germany, the UK, Japan, China, and Brazil. Ensuring a widespread reach, Eli Lilly and Co's presence remains significant on a global scale, contributing to its reputation as a leading pharmaceutical player.

What significant milestones has the company Eli Lilly and Co achieved?

Eli Lilly and Co, a renowned pharmaceutical company, has achieved significant milestones over the years. It pioneered the first commercially available insulin, revolutionizing diabetes treatment. The company also developed Prozac, a widely used antidepressant, contributing to mental health care. Eli Lilly collaboratively discovered Erbitux, an anti-cancer drug, which has transformed the treatment of colorectal cancer. Furthermore, the company introduced Humalog, a fast-acting insulin analog, enhancing diabetes management. Eli Lilly and Co has consistently demonstrated its commitment to innovation and improving patients' lives with its groundbreaking pharmaceutical developments.

What is the history and background of the company Eli Lilly and Co?

Eli Lilly and Co, founded in 1876, is a leading global pharmaceutical company headquartered in Indianapolis. With a rich history spanning over 140 years, Eli Lilly and Co has consistently focused on discovering, developing, and marketing innovative pharmaceutical products that improve people's lives. The company is committed to addressing crucial medical needs through its diverse portfolio of medicines and has made notable contributions in areas like diabetes, cancer, neuroscience, and immunology. Over the years, Eli Lilly and Co has established a strong reputation for its scientific expertise, ethical business practices, and dedication to ensuring patient safety and well-being.

Who are the main competitors of Eli Lilly and Co in the market?

The main competitors of Eli Lilly and Co in the market are pharmaceutical companies such as Pfizer, Johnson & Johnson, Merck & Co., Novartis, and Sanofi.

In which industries is Eli Lilly and Co primarily active?

Eli Lilly and Co is primarily active in the pharmaceutical industry.

What is the business model of Eli Lilly and Co?

The business model of Eli Lilly and Co. revolves around research, development, and commercialization of pharmaceutical products. As one of the leading global pharmaceutical companies, Eli Lilly focuses on discovering innovative medicines to treat diseases and improve patients' lives. Through extensive research and collaboration, the company develops a wide range of therapeutic solutions across various areas such as diabetes, oncology, immunology, and neuroscience. By consistently investing in R&D, Eli Lilly strives to bring new treatments to market, ensuring quality healthcare and offering value to patients, healthcare professionals, and stakeholders worldwide.

What is the P/E ratio of Eli Lilly and Co 2025?

The Eli Lilly and Co P/E ratio is 36.67.

What is the P/S ratio of Eli Lilly and Co 2025?

The Eli Lilly and Co P/S ratio is 13.27.

What is the Quality Investing of Eli Lilly and Co?

The Quality Investing for Eli Lilly and Co is 8/10.

What is the revenue of Eli Lilly and Co 2025?

The expected Eli Lilly and Co revenue is 59.8 B USD.

How high is the profit of Eli Lilly and Co 2025?

The expected Eli Lilly and Co profit is 21.63 B USD.

What is the business model of Eli Lilly and Co

Eli Lilly and Co is a globally active company in the healthcare sector. Its business model focuses on developing, manufacturing, and marketing innovative drugs and healthcare products to have positive impacts on people's lives. The company operates in three main business areas: human pharmaceuticals, animal health, and biotechnology. In the field of human pharmaceuticals, the company offers a wide range of drugs for the treatment of diseases such as diabetes, cancer, arthritis, neurology, and more. Some of its well-known products include Humalog, Trulicity, Taltz, Jardiance, Forteo, and Alimta. Eli Lilly and Co is also a major player in the animal health sector, providing veterinarians and pet owners with a wide range of drugs and services. This includes specialized products for the treatment of dogs, cats, horses, cattle, pigs, and poultry. Through its biotechnology business areas, Eli Lilly and Co is also dedicated to the development of innovative therapies and technologies. It focuses on autoimmune diseases, pain management, cancer research, and affordable healthcare in emerging markets. To ensure the success of its business model, Eli Lilly and Co invests billions annually in research and development of new drugs and healthcare solutions. A significant portion of these funds goes into clinical trials to ensure the safety and efficacy of the drugs. Eli Lilly and Co intends to further expand its business by focusing on partnerships, mergers, and acquisitions to expand its portfolio and capabilities. In this context, the company has recently undertaken a number of acquisitions and partnerships, including Loxo Oncology, ImClone Systems, Sitryx, Armo BioSciences, and AC Immune. Eli Lilly and Co generates revenue worldwide by selling its products directly to retailers, collaborating closely with doctors and other medical professionals, and selling its products to wholesalers and pharmacies. The company also operates its own facilities to provide medical services and products to people and pets. In summary, Eli Lilly and Co is a leading company in the healthcare sector that aims to provide innovative and life-changing solutions for patients and pets worldwide. Through research, development, and strategic partnerships, the company has built a wide range of products and extensive expertise to effectively serve its customers and expand its presence in the global healthcare market.

What is the Eli Lilly and Co dividend?

Eli Lilly and Co pays a dividend of 3.92 USD distributed over 4 payouts per year.

How often does Eli Lilly and Co pay dividends?

Eli Lilly and Co pays out a dividend 4 times a year.

What is the Eli Lilly and Co ISIN?

The ISIN of Eli Lilly and Co is US5324571083.

What is the Eli Lilly and Co WKN?

The WKN of Eli Lilly and Co is 858560.

What is the Eli Lilly and Co ticker?

The ticker of Eli Lilly and Co is LLY.

How much dividend does Eli Lilly and Co pay?

Over the past 12 months, Eli Lilly and Co paid a dividend of 4.52 USD . This corresponds to a dividend yield of about 0.51 %. For the coming 12 months, Eli Lilly and Co is expected to pay a dividend of 5.75 USD.

What is the dividend yield of Eli Lilly and Co?

The current dividend yield of Eli Lilly and Co is 0.51 %.

When does Eli Lilly and Co pay dividends?

Eli Lilly and Co pays a quarterly dividend. This is distributed in the months of June, September, December, March.

How secure is the dividend of Eli Lilly and Co?

Eli Lilly and Co paid dividends every year for the past 27 years.

What is the dividend of Eli Lilly and Co?

For the upcoming 12 months, dividends amounting to 5.75 USD are expected. This corresponds to a dividend yield of 0.65 %.

In which sector is Eli Lilly and Co located?

Eli Lilly and Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eli Lilly and Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eli Lilly and Co from 3/10/2025 amounting to 1.5 USD, you needed to have the stock in your portfolio before the ex-date on 2/14/2025.

When did Eli Lilly and Co pay the last dividend?

The last dividend was paid out on 3/10/2025.

What was the dividend of Eli Lilly and Co in the year 2024?

In the year 2024, Eli Lilly and Co distributed 4.52 USD as dividends.

In which currency does Eli Lilly and Co pay out the dividend?

The dividends of Eli Lilly and Co are distributed in USD.

All fundamentals about Eli Lilly and Co

Our stock analysis for Eli Lilly and Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eli Lilly and Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.